Travere Therapeutics Inc

TVTX

Add to Watchlist

42.590USD

-1.510-3.42%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Travere Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

29 / 382

Overall Ranking

125 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Travere Therapeutics Inc Highlights

StrengthsRisks

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 237.88% year-on-year.

Undervalued

The company’s latest PE is -190.46, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 113.81M shares, decreasing 0.92% quarter-over-quarter.

Held by Joel Greenblatt

Star Investor Joel Greenblatt holds 55.98K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.40.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

53.538

Target Price

+21.40%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Travere Therapeutics Inc is 7.17, ranking 114 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 127.20M, representing a year-over-year increase of 55.63%, while its net profit experienced a year-over-year increase of 10.00%.

Score

Industry at a Glance

Previous score

7.17

Change

0



Financials

5.82

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

4.50

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.16

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.37

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Travere Therapeutics Inc is 6.75, ranking 216 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -190.46, which is -99.11% below the recent high of -1.70 and -5.45% above the recent low of -200.83.

Score

Industry at a Glance

Previous score

6.75

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 29/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Travere Therapeutics Inc is 8.53, ranking 106 out of 382 in the Biotechnology & Medical Research industry. The average price target is 41.00, with a high of 49.00 and a low of 31.00.

Score

Industry at a Glance

Previous score

8.67

Change

-0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Travere Therapeutics Inc is 6.97, ranking 118 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 48.02 and the support level at 37.76, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.18

Change

-0.21

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Travere Therapeutics Inc is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 122.39%, representing a quarter-over-quarter increase of 4.06%. The largest institutional shareholder is James Simons, holding a total of 1.97M shares, representing 2.12% of shares outstanding, with 30.51% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

10.51M

-0.83%

BlackRock Institutional Trust Company, N.A.

6.49M

-2.71%

Fidelity Management & Research Company LLC

5.88M

+133.01%

State Street Investment Management (US)

4.76M

+47.82%

Perceptive Advisors LLC

4.28M

-4.84%

Nomura Investment Management Business Trust

3.77M

-24.29%

Armistice Capital LLC

3.76M

-44.02%

Fidelity Institutional Asset Management

3.00M

+1405.59%

Adage Capital Management, L.P.

2.93M

-17.60%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Travere Therapeutics Inc is 5.51, ranking 43 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.12. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Travere Therapeutics Inc

TVTX

7.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment